AATB Submits Formal Comments on FDA Draft Guidance for Sepsis and MTB

Today, AATB submitted formal comments to the Food and Drug Administration (FDA) in response to the draft guidance documents issued on May 2, 2025. 

Join Us: 2025 AATB Annual Meeting Registration Now Open!

We are thrilled to announce that registration is officially open for the 2025 AATB Annual Meeting!

Register Now for the 2025 CTBS Exam and Start Your Path to Certification

We’re excited to announce that registration for the 2025 Certified Tissue Bank Specialist (CTBS) Exam is officially open!

AATB Election for Board of Governors Officers and At-Large Governors – Meet the Candidates

The AATB biennial election for the 2025–2027 Board of Governors opens on June 2. Learn more about the candidates and help shape the future of AATB.

AATB Announces Formation of 501(c)(6) Organization the Association for Advancing Tissue and Biologics

In 2024, the American Association of Tissue Banks (AATB) underwent a comprehensive strategic planning process that identified the need to strengthen and protect our association’s ability to engage in advocacy, policy, and industry promotion.

FDA Reissues Sepsis and Mtb Guidance Documents as Draft for Public Comment

AATB has learned that the US Food and Drug Administration (FDA) has reissued the following guidance documents as drafts, with a public comment period open through July 7, 2025.

Bulletin 25-2

OMB Reviewing Final Guidance Documents on Sepsis and Mtb

On April 18, 2025, the White House Office of Management and Budget (OMB) received the two guidance documents from the US Food and Drug Administration (FDA) for final review under the Administration’s mandate to evaluate guidance issued during the previous administration.

Nominations by Petition for AATB 2025-2027 Board of Governors

AATB is seeking nominations for the AATB Board of Governors in the following leadership positions: Chairperson-Elect, Secretary-Treasurer, and At-Large Governors (2).

AATB Advocacy Helps Secure Delay in CMS LCD Implementation for Skin Substitute Grafts

On Friday, April 11, the Centers for Medicare & Medicaid Services (CMS) announced that the final Local Coverage Determinations (LCDs) for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers will now take effect on January 1, 2026.